Most Semaglutide side effects are mild, dose-related and settle as treatment continues. The reactions that matter clinically are rare but need to be recognised quickly.
Key takeaways
- Common effects: nausea, constipation, reflux, fatigue, gallbladder events.
- Avoid Semaglutide in personal or family history of medullary thyroid carcinoma or MEN2.
- Dose-related effects often resolve by stepping back one strength.
- Severe or persistent reactions warrant stopping and seeking review.
Frequency bands
| Frequency | Reactions | Action |
|---|---|---|
| Very common (>10%) | nausea, constipation | Usually self-limiting; supportive measures and reassurance. |
| Common (1–10%) | reflux, fatigue, gallbladder events | Review dose and timing; consider dose reduction. |
| Uncommon (<1%) | hypersensitivity, marked laboratory changes | Stop and arrange clinical assessment. |
| Rare | serious organ-specific reactions | Stop immediately; urgent medical attention. |
Reducing the burden
Take Semaglutide exactly as directed: weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg. Splitting titration into smaller steps, dosing with food where the label allows, and hydrating well cover most tolerability problems seen in practice.
Semaglutide at a glance
| Attribute | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist |
| Common brand | Ozempic / Wegovy / Rybelsus |
| Licensed use | type 2 diabetes and chronic weight management |
| Available strengths | 0.25–2.4 mg pen; 3, 7, 14 mg oral |
| Dosage form | prefilled pen / oral tablet |
| Typical onset | appetite effects within days, weight plateau at 60–68 weeks |
| Duration / dosing interval | 7-day half-life, once-weekly dosing |
| Storage | 2–8 °C cold chain until first use |
